Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calenduloside E is a natural pentacyclic triterpenoid saponin primarily isolated from the root bark of *Aralia elata* (Miq.) Seem. It is characterized by its anti-atherosclerotic and vasoprotective properties, specifically demonstrating the ability to protect human umbilical vein endothelial cells (HUVECs) from injury induced by oxidized low-density lipoprotein (ox-LDL). Its primary mechanism of action involves binding to the Heat shock protein 90 beta (HSP90β) isoform, specifically interacting with the Asp93 residue in the protein's regulatory pocket. Although it shows potential as a therapeutic lead for cardiovascular diseases, its clinical application has been hampered by relatively weak potency and a narrow therapeutic index, leading researchers to develop synthetic derivatives (such as hybridization with ticagrelor fragments) to enhance its binding affinity and efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calenduloside e.